Diabetes Is Still a Risk Factor for Restenosis After Drug-Eluting Stent in Coronary Arteries

  1. André J. Scheen, MD, PHD1 and
  2. Fabian Warzée1
  1. 1Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire, Sart Tilman, Liège, Belgium
  1. Address correspondence to André J. Scheen, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire, Sart Tilman (B35), B-4000 Liège, Belgium. E-mail: andre.scheen{at}chu.ulg.ac.be

We read with interest the meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting (1). This meta-analysis of six clinical trials showed that the odds ratio (OR) of coronary artery restenosis associated with diabetes was 1.61 (95% CI 1.21–2.14, P = 0.004) in univariate logistic regression models, but it decreased to 1.30 (0.99–1.70, P = 0.055) after age was controlled in multivariate models. All trials selected in this meta-analysis used classical bare-metal stents. However, drug-eluting stents (DESs) have been shown to improve outcomes among patients undergoing percutaneous coronary intervention by significantly reducing restenosis rates (2).

We performed …

| Table of Contents